Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Feb;87(1):17-21.
doi: 10.1136/sti.2010.042622. Epub 2010 Jul 18.

Estimating the risk of HIV transmission from homosexual men receiving treatment to their HIV-uninfected partners

Affiliations

Estimating the risk of HIV transmission from homosexual men receiving treatment to their HIV-uninfected partners

Timothy B Hallett et al. Sex Transm Infect. 2011 Feb.

Abstract

Objective: To determine how the risk of HIV transmission from homosexual men receiving antiretroviral treatment is related to patterns of patient monitoring and condom use.

Methods: A stochastic mathematical simulation model was developed of cohorts of men in the Netherlands who have sex with men (MSM), defining the parameters of the model using observational cohort data. The model incorporates viral load trends during first-line treatment, patient monitoring and different scenarios for the way in which condom use may depend on recent viral load measurements. The model does not include the effect of sexually transmitted infections on HIV transmission.

Results: For MSM receiving treatment, the risk of transmitting HIV to their long-term partner is 22% (uncertainty interval: 9-37%) if condoms are never used. With incomplete use (in 30% of sex acts) the risk is reduced slightly, to 17% (7-29%). However, the risk is as low as 3% (0.2-8%) when men receiving treatment use condoms only 6 months beyond their last undetectable viral load measurement. The risk is further reduced when 3 months is the time period beyond which condoms are used.

Conclusions: When condom use by HIV-infected men receiving combination treatment with antiretroviral agents is based on their last viral load measurement, the transmission risk is much lower than with incomplete condom use. The key message for patients is that although always using condoms during treatment is the best way to protect partners from the risk of HIV transmission, when such use cannot be achieved, the second best strategy is to use condoms whenever the last undetectable viral load was measured more than 3 months ago.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None.

Figures

Figure 1
Figure 1
Schematic representation of the three assumed trajectories of (log) viral load after treatment initiation: (i) suppression achieved and adherence good (dotted line); (ii) suppression achieved but adherence poor (solid line); and (iii) suppression not achieved (dashed line). The circles indicate when the regimen was changed. Parameter values are presented in table 1 and details are provided in the online supplementary appendix.
Figure 2
Figure 2
Probability of transmission to partner during first-line treatment, if condoms are never used; condoms are used 30% of the time; (iii) condoms are used unless last viral load (VL) measurement in the past 6 months was undetectable; or always using condoms. Error-bars show the 95% uncertainty interval, as described in the text. It is assumed that the partnership is maintained over the entire course of first-line treatment and that viral load is related to transmission rate, as Fraser et al have described.
Figure 3
Figure 3
The influence of (A) monitoring frequency and (B) loss to follow-up on the probability of HIV transmission, assuming condoms are used unless last viral load measurement in the past 6 months was undetectable. It is assumed that the partnership is maintained over the entire course of first-line treatment and that viral load is related to transmission rate, as Fraser et al have described.

References

    1. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997;337:725–33 - PubMed
    1. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999;341:1865–73 - PubMed
    1. UNAIDS Report on the Global AIDS epidemic, http://www.unaids.org/en/knowledge/HIVdata/globalreport/2008/2008_global..., 2008
    1. Jahn A, Floyd S, Crampin AC, et al. Population-level effect of HIV on adult mortality and early evidence of reversal after introduction of antiretroviral therapy in Malawi. Lancet 2008;371:1603–11 - PMC - PubMed
    1. When To Start Consortium, Sterne JA, May M, Costagliola D, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009;373:1352–63 - PMC - PubMed

Publication types

Substances